The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma

Author:

Kirchner M.,Kluck K.,Brandt R.,Volckmar A.-L.,Penzel R.,Kazdal D.,Endris V.,Neumann O.,Seker-Cin H.,Goldschmid H.,Glade J.,Allgäuer M.,Kriegsmann M.,Winter H.,Muley T.,Perner S.,Frost N.,Reck M.,Fröhling S.,Schirmacher P.,Thomas M.,Budczies J.,Christopoulos P.,Stenzinger A.

Funder

Boehringer Ingelheim

Pfizer

Deutsche Zentrum für Lungenforschung

Roche

Bristol-Myers Squibb

Meso Scale Diagnostics

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference61 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer;Vyse;Signal Transduct Target Ther,2019

3. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2018

4. Clinical, structural and biochemical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer;Yasuda;Sci Transl Med,2013

5. Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors;Kosaka;Cancer Res,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3